InChI=1S/C23H39NO6S/c1-2-3-4-5-6-8-12-18(25)13-9-7-10-15-21(31-17-19(24)23(29)30)20(26)14-11-16-22(27)28/h6-10,15,18-21,25-26H,2-5,11-14,16-17,24H2,1H3,(H,27,28)(H,29,30)/b8-6-,9-7+,15-10+/t18-,19+,20+,21-/m1/s1 |
FZJOTYMARNGISF-SHPAXQKOSA-N |
C(/C=C\CCCCC)[C@H](C/C=C/C=C/[C@H]([C@@H](O)CCCC(=O)O)SC[C@H](N)C(=O)O)O |
|
Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
Bronsted acid
A molecular entity capable of donating a hydron to an acceptor (Bronsted base).
(via oxoacid )
|
|
human xenobiotic metabolite
Any human metabolite produced by metabolism of a xenobiotic compound in humans.
|
|
View more via ChEBI Ontology
Outgoing
|
(12R)-hydroxy-10,11-dihydroleukotriene E4
(CHEBI:134418)
has role
human xenobiotic metabolite
(CHEBI:76967)
(12R)-hydroxy-10,11-dihydroleukotriene E4
(CHEBI:134418)
is a
L-cysteine thioether
(CHEBI:27532)
(12R)-hydroxy-10,11-dihydroleukotriene E4
(CHEBI:134418)
is a
amino dicarboxylic acid
(CHEBI:36164)
(12R)-hydroxy-10,11-dihydroleukotriene E4
(CHEBI:134418)
is a
diol
(CHEBI:23824)
(12R)-hydroxy-10,11-dihydroleukotriene E4
(CHEBI:134418)
is a
leukotriene
(CHEBI:25029)
(12R)-hydroxy-10,11-dihydroleukotriene E4
(CHEBI:134418)
is a
non-proteinogenic L-α-amino acid
(CHEBI:83822)
(12R)-hydroxy-10,11-dihydroleukotriene E4
(CHEBI:134418)
is a
secondary alcohol
(CHEBI:35681)
(12R)-hydroxy-10,11-dihydroleukotriene E4
(CHEBI:134418)
is conjugate acid of
(12R)-hydroxy-10,11-dihydroleukotriene E4(1−)
(CHEBI:133320)
|
|
Incoming
|
(12R)-hydroxy-10,11-dihydroleukotriene E4(1−)
(CHEBI:133320)
is conjugate base of
(12R)-hydroxy-10,11-dihydroleukotriene E4
(CHEBI:134418)
|
(5S,6R,7E,9E,12R,14Z)-6-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-5,12-dihydroxyicosa-7,9,14-trienoic acid
|
(5S,6R,12R)-Dihydroxy-6-(S-cysteinyl)-(7E,9E,14Z)-eicosatrienoic acid
|
HMDB
|
5,12-Dihydroxy-6-cysteinyl-7,9,14-eicosatrienoic acid
|
HMDB
|
5S,12R-Dihydroxy-6-S-cysteinyl-7E,9E,14Z-eicosatrienoic acid
|
HMDB
|
ELTB3
|
HMDB
|
8244977
|
PubMed citation
|
Europe PMC
|
|